MedPath

The clinical research of effect of YiGuanJian Decoction on liver cirrhosis post HBV (Liver-Kidney Yin deficiency syndrome)

Phase 1
Recruiting
Conditions
liver cirrhosis post HBV
Registration Number
ITMCTR2000003798
Lead Sponsor
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) Ages 18 to 65, regardless of gender;
(2) It conforms to the western medicine diagnostic criteria of liver cirrhosis post HBV, and the TCM syndrome differentiation criteria of liver-kidney Yin deficiency syndrome, and the CTP score is 7-9 points (Grade B);
(3) Patients who are taking or preparing to take Entecavir;
(4) The person or his guardian agrees to participate in the randomized controlled trial and signs the informed consent.

Exclusion Criteria

(1) Liver failure;
(2) Hepatitis with other hepatitis virus infection, fatty liver, long-term alcohol consumption or other chronic severe hepatitis;
(3) Women who are pregnant or preparing for pregnancy, or women who are breastfeeding;
(4) Severe underlying diseases: severe COPD, severe renal insufficiency, chronic congestive heart failure, etc.
(5) Patients with immunodeficiency, such as malignant tumor, organ transplantation and taking immunosuppressive drugs or glucocorticoids within the last 3 months;
(6) Patients participating in other clinical trials;
(7) Other conditions that the researcher believes are not suitable for inclusion.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Ā© 2025 MedPath, Inc. All rights reserved.